Abstract:BackgroundThe androgen receptor (AR) is an emerging prognostic marker and therapeutic target in breast cancer. AR is expressed in 60–80% of breast cancers, with higher prevalence among estrogen receptor-positive (ER+) tumors. Androgen treatment inhibits ER signaling in ER+/AR+ breast cancer cell lines, and AR expression is associated with improved survival for this subtype in epidemiologic studies. However, whether AR expression modifies the efficacy of selective ER modulators or aromatase inhibitors for ER+ cancers remains unclear.MethodsWe evaluated the prognostic and predictive value of AR expression among 3021 postmenopausal ER+ breast cancer patients in the Breast International Group (BIG) trial 1–98. The BIG 1–98 study was a four-armed, double-blind, phase III randomized clinical trial that compared 5 years of tamoxifen or letrozole monotherapy, or sequences of 2 years and 3 years treatment with one drug and then the other. AR expression was measured by immunohistochemistry and the percentage of AR-positive nuclei was quantified. The association between AR expression and prognosis was evaluated using Cox proportional hazards models. Continuous AR-by-treatment interactions were assessed using Subpopulation Treatment Effect Pattern Plots (STEPP).ResultsEighty-two percent of patients had AR+ (≥ 1%) tumors. Patients with AR+ cancers were more likely to have smaller, lower-grade tumors, with higher expression of ER and PR. AR expression was not associated with breast cancer-free interval (BCFI) (415 events) over a median 8.0 years of follow-up (p = 0.12, log-rank test). In multivariable-adjusted models, AR expression was not associated with BCFI (HR = 1.07, 95% CI 0.83–1.36, p = 0.60). The letrozole versus tamoxifen monotherapy treatment effect did not significantly differ for AR+ tumors (HR = 0.63, 95% CI 0.44–0.75, p = 0.003) and AR− tumors (HR = 0.39, 95% CI 0.21–0.72, p = 0.002) (p-heterogeneity = 0.16). STEPP analysis also suggested no heterogeneity of the treatment effect across the continuum of AR expression.ConclusionsAR expression was not associated with prognosis, nor was there heterogeneity of the letrozole versus tamoxifen treatment effect by AR expression. These findings suggest that AR expression may not be an informative biomarker for the selection of adjuvant endocrine therapy for postmenopausal women with ER+ breast cancers.Trial registrationClinicalTrials.gov, NCT00004205, Registered 27 January 2003—Retrospectively registered, https://clinicaltrials.gov/ct2/show/study/NCT00004205.

Androgen Receptor in Breast Cancer: from Bench to Bedside

Expression of Androgen Receptor in Breast Cancer and Its Prognostic Significance

Androgen receptor expression and clinical characteristics in breast cancer

The effect of androgen receptor expression on clinical characterization of metastatic breast cancer

Androgen receptor transcriptionally inhibits programmed death ligand-1 (PD-L1) expression and influences immune escape in bladder cancer

Androgen receptor inhibitors in treating prostate cancer

Treatments Targeting the Androgen Receptor and Its Splice Variants in Breast Cancer

The Prognostic Values of Androgen Receptor in Breast Cancer

Androgen receptor expression and association with clinicopathological features and prognosis in early stage triple-negative breast cancer

The Prognostic Values of Androgen Receptor in Breast Cancer A Hospital-Based Retrospective and Propensity Score-Matched Cohort

The Role of Androgen Receptor in Prostate Cancer

Androgen Receptor-Related Non-coding RNAs in Prostate Cancer

The Androgen Receptor Promotes Cellular Proliferation by Suppression of G-Protein Coupled Estrogen Receptor Signaling in Triple-Negative Breast Cancer

The androgen receptor interacts with GATA3 to transcriptionally regulate a luminal epithelial cell phenotype in breast cancer

Androgen Receptor Signaling Pathway in Prostate Cancer: From Genetics to Clinical Applications

Diversity in Androgen Receptor Action Among Treatment-naïve Prostate Cancers Is Reflected in Treatment Response Predictions and Molecular Subtypes

Therapeutic Targets and Predictive Markers of Treatment Efficacy of Bladder Cancer

Prognostic and predictive value of androgen receptor expression in postmenopausal women with estrogen receptor-positive breast cancer: results from the Breast International Group Trial 1–98

Antibody–drug conjugates for breast cancer: a bibliometric study and clinical trial analysis

Androgen receptor: what we know and what we expect in castration-resistant prostate cancer

Correlation between Androgen Receptor Expression in Luminal B (HER–2 Negative) Breast Cancer and Disease Outcomes